Sign In
Buy CNTA
$40.50
+0 (+0%)
At Close: Jul 23, 2026
Mario Alberto Accardi PhD, President and founder of Centessa's Orexin Program, appointed Chief Executive Officer and member of the Board of Directors Mario Alberto Accardi PhD, President and founder o
What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company
01:48pm, Saturday, 29'th Nov 2025
San Francisco-based 5AM Venture Management sold 150,000 CNTA shares in the third quarter. Despite the sale, the stock's sharp rally last quarter led the fund's net position value in CNTA to increase b
Campbell & CO Investment Adviser LLC Acquires New Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA
03:53am, Tuesday, 18'th Nov 2025
Campbell and CO Investment Adviser LLC bought a new position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ: CNTA) during the second quarter, according to its most recent filing with
Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying
11:15am, Monday, 17'th Nov 2025
California-based TCG Crossover Management increased its stake in Centessa Pharmaceuticals by 245,664 shares in the third quarter for an estimated $38.1 million. The transaction value equaled about 0.2
Why Centessa Pharmaceuticals Stock Crushed the Market Today
06:27pm, Wednesday, 12'th Nov 2025
It's gearing up to take in a flood of fresh capital. This is being effected in a secondary issue of its ADSes.
Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
08:40pm, Tuesday, 11'th Nov 2025
BOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced the pricing of an underwritten public offerin
Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
04:00pm, Tuesday, 11'th Nov 2025
BOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that it has commenced an underwritten public
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
08:00am, Friday, 07'th Nov 2025
BOSTON and LONDON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines
46,665 Shares in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Purchased by Y Intercept Hong Kong Ltd
03:40am, Thursday, 06'th Nov 2025
Y Intercept Hong Kong Ltd purchased a new position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ: CNTA) in the undefined quarter, according to the company in its most recent 13F fili
BOSTON and LONDON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported financial results for the third quarter ended
Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
07:00am, Wednesday, 03'rd Sep 2025
BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
07:00am, Tuesday, 12'th Aug 2025
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year
Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Cente
Centessa Pharmaceuticals (CNTA) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Monday, 16'th Jun 2025
Centessa Pharmaceuticals (CNTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (F
